Status:
RECRUITING
Bradykinin-degradating Enzymes Activities in Angiotensin-Converting Enzyme Inhibitors-associated Angioedema
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
University Hospital, Paris
University Hospital, Rouen
Conditions:
Angio-Oedema Caused by Angiotensin-Converting-Enzyme Inhibitor
Eligibility:
All Genders
18+ years
Brief Summary
Angiotensin-Converting-Enzyme-inhibitors-dependent angioedema (ACEi-AE) is the most frequent form of bradykinin-mediated AE, with an estimated prevalence of 0.1% to 0.7%. These AE can be explained by...
Eligibility Criteria
Inclusion
- Men and women at least 18 years old
- Presenting AE secondary to treatment with Angiotensin Conversion Enzyme Inhibitors for less than 15 days, or an isolated AE (without superficial hives), which lasts at least 15 hours, and whose diagnosis is validated by the expert committee,
- Having signed informed and written consent
- And being affiliated with social security
Exclusion
- Patient who had one or more AEs prior to IEC
- Hereditary or acquired deficiency of C1 inhibitor
- Subject with known mutation of the F12 or PLG gene Subject in times of exclusion from another research involving the human person type 1 or 2 Persons referred to in sections L1121-5 to L1121-8 of the public health code (pregnant woman, breastfeeding mother, person deprived of liberty, person subject to legal protection) subject that cannot be contacted in an emergency situation
Key Trial Info
Start Date :
October 27 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 26 2025
Estimated Enrollment :
243 Patients enrolled
Trial Details
Trial ID
NCT04763577
Start Date
October 27 2021
End Date
October 26 2025
Last Update
February 25 2025
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu Grenoble Alpes
Grenoble, France, 38043
2
CHRU de Lille _Hôpital Claude-Huriez
Lille, France, 59037
3
AP-HP _St Antoine
Paris, France, 75571
4
CHU de Rouen
Rouen, France, 76 031